Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 9/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921275 | 0.88 | GABRG2 (0.43) | LCKBTKTSHRMAPK10 | |
| SCHEMBL2669395 | 0.87 | NPY1R (0.37) | LCKBTKCYP1A2TSHRMAPK10 | |
| SCHEMBL2669396 | 0.86 | PARP1 (0.35) | TSHRMAPK10BMPR1AACVRL1ACVR1 | |
| SCHEMBL4924879 | 0.85 | TSHR (0.35) | TSHRMAPK10BMPR1AACVRL1ACVR1 | |
| SCHEMBL4924422 | 0.84 | LCK (0.51) | LCKBTKCYP17A1CYP1A2MAP4K1 | |
| SCHEMBL2662058 | 0.84 | GABRG2 (0.44) | LCKBTKCYP17A1CYP1A2TSHR | |
| SCHEMBL2661491 | 0.84 | MAPK1 (0.35) | BMPR1AACVRL1ACVR1 | |
| SCHEMBL4924467 | 0.84 | HRH4 (0.41) | BMPR1AACVRL1ACVR1 | |
| SCHEMBL2656099 | 0.83 | PARP1 (0.35) | TSHRMAPK10BMPR1AACVRL1ACVR1 | |
| SCHEMBL2660877 | 0.82 | MAPK1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | LCK 4253/4885BTK 2744/4885CYP17A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.